Summit Therapeutics (SMMT) reported a Q3 adjusted loss Wednesday of $0.05 per diluted share, wider than the loss of $0.03 a year earlier.
Analysts polled by Capital IQ expected a loss of $0.05.
Total operating expenses for the quarter ended Sept. 30 were $58.1 million, up from $20.7 million a year earlier.
As of Sept. 30, the company said it had $487 million in cash and or cash equivalents on hand.
Price: 21.52, Change: -0.31, Percent Change: -1.42
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments